Meeting
2021 Genitourinary Cancers Symposium
Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.
Authors
Pavlos Msaouel
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Pavlos Msaouel , Jianjun Gao , Ying Yuan , Arlene O. Siefker-Radtke , Eric Jonasch , Sangeeta Goswami , Amado J. Zurita , Matthew T Campbell , Amishi Yogesh Shah , Paul G. Corn , Claudia Ramos , Xiaohong Yan , Curtis Chin , Hirak Der-Torossian , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04518046
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS365)
DOI
10.1200/JCO.2021.39.6_suppl.TPS365
Abstract #
TPS365
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors.
First Author: Toni K. Choueiri
Poster
2020 ASCO Virtual Scientific Program
A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.
First Author: Toni K. Choueiri
Poster
2018 ASCO Annual Meeting
Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
First Author: Shubham Pant
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.
First Author: Daniel E. Castellano